Teleflex (NYSE: TFX) announced today that it completed its previously announced acquisition of the Biotronik Vascular Intervention (VI) business.
As part of strategy shifts by both companies, Teleflex in February agreed to acquire substantially all of the Biotronik VI unit. The acquisition adds a broad portfolio of therapeutic products to the Wayne, Pennsylvania-based company’s interventional access products. Teleflex says the new business can also help establish its footprint in the growing peripheral intervention market.
The VI business features products like the Orsiro drug-eluting stent, Pantera Lux drug-coated balloon catheter, PK Papyrus stent and Freesolve resorbable magnesium scaffold. Biotronik, meanwhile, says the move reflects its commitment to active implantable devices.
“We are pleased to announce the completion of the acquisition of substantially all of the Vascular Intervention business of Biotronik earlier than expected,” said Liam Kelly, chair, president and CEO of Teleflex. “The acquisition will significantly enhance our global presence in the cath lab, expand our suite of innovative technologies, and improve patient care. We believe the acquisition will allow us to position this advanced coronary portfolio alongside our existing Interventional business and establish our global footprint in the fast-growing peripheral intervention market.
“The acquired business is rooted in robust research and development, clinical expertise, and global manufacturing capabilities, which we believe will further bolster Teleflex’s innovation pipeline, and position the company to participate in the emerging potential for resorbable scaffold technologies. We will provide additional details on our second quarter earnings conference call.”
More details on the Teleflex acquisition of Biotronik’s VI business
Under the deal struck in February, Teleflex agreed to pay nearly $900 million €760 million to buy the Biotronik business.
Teleflex says the acquisition importantly gives it the opportunity to invest in and expand the clinical trial program for Freesolve. The sirolimus-eluting resorbable metallic scaffold (RMS) received CE mark in February 2024. Teleflex hopes to initiate a U.S. pivotal study for the technology.
According to Teleflex, given its earlier-than-expected completion, the acquisition should generate revenues of $204 million in the second half of 2025. It expects $105 million in sales for the fourth quarter, as previously expected. Beginning in 2026, the company expects annual revenue growth of 6% or better for the acquired products.
Teleflex expects a 10¢ accretive impact to its adjusted earnings per share (EPS) in the first year of ownership. After that, it anticipates an increasingly accretive impact.
